Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

In part 1 of a phase 2–3 trial, a 50-μg dose of mRNA-1273 vaccine was safe and immunogenic. In part 2, nearly 4000 6-to-11-year-olds received two doses of vaccine or placebo and were followed for a median of 82 days. The vaccine had mainly mild adverse effects and was immunogenic in 99%, similar to...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 386; číslo 21; s. 2011 - 2023
Hlavní autoři:	Creech, C. Buddy, Anderson, Evan, Berthaud, Vladimir, Yildirim, Inci, Atz, Andrew M., Melendez Baez, Ivan, Finkelstein, Daniel, Pickrell, Paul, Kirstein, Judith, Yut, Clifford, Blair, Ronald, Clifford, Robert A., Dunn, Michael, Campbell, James D., Montefiori, David C., Tomassini, Joanne E., Zhao, Xiaoping, Deng, Weiping, Zhou, Honghong, Ramirez Schrempp, Daniela, Hautzinger, Kelly, Girard, Bethany, Slobod, Karen, McPhee, Roderick, Pajon, Rolando, Das, Rituparna, Miller, Jacqueline M., Schnyder Ghamloush, Sabine
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 26.05.2022
Témata:	2019-nCoV Vaccine mRNA-1273 - adverse effects 2019-nCoV Vaccine mRNA-1273 - immunology 2019-nCoV Vaccine mRNA-1273 - therapeutic use Adolescent Adolescent Medicine Adult Adverse events Age Age groups Antibodies Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Child Childhood Diseases Children Coronavirus Coronaviruses COVID-19 - blood COVID-19 - complications COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects COVID-19 Vaccines - therapeutic use Double-Blind Method FDA approval Heart diseases Humans Immune response Immunization Immunogenicity Infections Infectious Disease Infectious diseases Inflammation Injection Injections mRNA Multisystem inflammatory syndrome in children Myocarditis Original Pediatrics Pericarditis Placebos Population Public health Safety SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Systemic Inflammatory Response Syndrome Teenagers Vaccination Vaccine Efficacy Vaccines Viral Infections Young Adult Young adults United States > US
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	In part 1 of a phase 2–3 trial, a 50-μg dose of mRNA-1273 vaccine was safe and immunogenic. In part 2, nearly 4000 6-to-11-year-olds received two doses of vaccine or placebo and were followed for a median of 82 days. The vaccine had mainly mild adverse effects and was immunogenic in 99%, similar to the results in 18-to-25-year-olds. Vaccine efficacy during a delta-variant period was 88%.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 A list of the KidCOVE Study Group members is provided in the Supplementary Appendix, available at NEJM.org.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2203315